Physician

Daniel Farray-Berges, M.D.

According to 2025 Medicare claims, Daniel Farray-Berges, M.D. (NPI: 1639116288) practices hematology/oncology in the McAllen-Edinburg-Mission, TX market, with the plurality of this provider's patient population coming from Hidalgo, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 78596-6608.

Farray-Berges' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 317 traditional Medicare patients, billed 88,735 HCPCS/CPT codes, and received $1,538,165 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,694 prescription claims across 443 beneficiaries totaling $7,805,282 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 40 claims. Open Payments data shows 26 records totaling $32,952. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $954,940 and ending at $1,538,165. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,726,236 to $7,805,282. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	529	82,238	$954,940
2016	585	88,654	$1,602,132
2017	596	105,187	$1,884,790
2018	614	136,350	$2,429,088
2019	582	129,636	$2,166,865
2020	483	98,916	$1,842,799
2021	407	85,740	$1,492,985
2022	382	102,264	$1,890,474
2023	341	84,060	$1,586,287
2024	317	88,735	$1,538,165

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	260	1,643	$1,726,236
2016	260	1,688	$1,801,884
2017	276	1,856	$1,851,468
2018	296	2,160	$2,638,360
2019	332	2,062	$3,203,206
2020	330	2,130	$4,080,000
2021	332	2,259	$4,741,641
2022	360	2,268	$5,940,861
2023	392	2,499	$7,177,838
2024	443	2,694	$7,805,282

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	65	$6,538
2016	N/R	73	$27,223
2017	N/R	46	$8,362
2018	12	44	$6,796
2019	N/R	26	$2,852
2020	N/R	58	$6,131
2021	11	30	$4,063
2022	N/R	29	$1,221
2023	N/R	40	$11,982
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	106	316	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	164	247	$60
80053	Blood test, comprehensive group of blood chemicals	164	440	$10
36415	Insertion of needle into vein for collection of blood sample	187	645	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	210	726	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	77	1,850	$1,095,770
Cabometyx	Cabozantinib S-Malate	38	1,204	$817,246
Ibrance	Palbociclib	50	1,393	$772,847
Verzenio	Abemaciclib	46	1,288	$687,320
Lenvima	Lenvatinib Mesylate	25	750	$573,486

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	15	$414	E.R. Squibb & Sons, L.L.C.
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$32,538	Epizyme, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Farray-Berges, M.D.?

Tedicare shows public-source Medicare data for Daniel Farray-Berges, M.D. (NPI 1639116288), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Farray-Berges, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Daniel Farray-Berges, M.D.?

Daniel Farray-Berges, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Daniel Farray-Berges, M.D. have Open Payments data?

Daniel Farray-Berges, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.